ZDHHC17

ZDHHC17 (HIP14) is a Golgi-localized palmitoyl acyltransferase that S-acylates a broad repertoire of neuronal and signaling substrates—including SNAP-25, PSD-95, huntingtin, DLK, NMNAT2, Smad7, and HSP90α—thereby governing synaptic protein clustering, vesicular trafficking, axon integrity, TGF-β signaling, and lysosome biogenesis (PMID:15603740, PMID:33207199, PMID:38876303, PMID:12393793). Substrate recruitment is mediated by an N-terminal ankyrin repeat domain that recognizes a [VIAP][VIT]XXQP linear motif (zDABM), though zDABM-independent acylation also occurs via distinct substrate-binding surfaces (PMID:26198635, PMID:36442513). Wild-type huntingtin potentiates ZDHHC17 enzymatic activity, whereas polyglutamine-expanded mutant huntingtin impairs the interaction and reduces substrate palmitoylation, linking ZDHHC17 dysfunction to Huntington disease-like neuropathology in knockout mice (PMID:21636527, PMID:21775500, PMID:16699508). Loss of ZDHHC17 in adult mice causes rapidly progressive paralysis, striatal synaptic failure, and gliosis, establishing it as essential for ongoing neuronal maintenance (PMID:27927242, PMID:24277827).

1. 2002 High

   Establishing that HIP14 localizes to the Golgi and cytoplasmic vesicles and functions in intracellular trafficking answered the foundational question of where and in what process this DHHC-domain protein acts.

   Evidence Subcellular fractionation/immunofluorescence in mammalian cells and genetic complementation of yeast akr1Δ endocytosis defect

   PMID:12393793

   Open questions at the time

   • Enzymatic activity not yet demonstrated
   • Mammalian substrates unknown
   • Mechanism of trafficking function undefined
2. 2004 High

   Demonstrating that HIP14 is a palmitoyl transferase with defined substrate specificity for neuronal proteins (SNAP-25, PSD-95, GAD65, synaptotagmin I, HTT) and that its depletion reduces synaptic protein clustering established ZDHHC17 as a bona fide PAT with neuronal function.

   Evidence Biochemical palmitoylation assays with substrate specificity panel and siRNA knockdown in neurons with fluorescence clustering readout

   PMID:15603740

   Open questions at the time

   • Palmitoylation sites on substrates not mapped
   • Substrate recognition mechanism unknown
   • In vivo relevance not tested
3. 2006 High

   Identifying HTT Cys214 as the HIP14-palmitoylated residue and showing that polyglutamine expansion reduces both the HIP14–HTT interaction and HTT palmitoylation, increasing inclusion formation and toxicity, directly linked defective palmitoylation to Huntington disease pathology.

   Evidence Acyl-RAC assay, Cys214 mutagenesis, co-IP of HTT–HIP14, siRNA/overexpression with inclusion formation readout in neurons

   PMID:16699508

   Open questions at the time

   • Whether HIP14 dysfunction is causal in HD in vivo not yet shown
   • Mechanism by which polyQ expansion reduces binding unclear
4. 2011 High

   Two complementary studies resolved the in vivo significance: wild-type HTT was shown to potentiate HIP14 enzymatic activity (lost with mutant HTT), and Hip14-knockout mice exhibited reduced substrate palmitoylation and HD-like neuropathology, establishing ZDHHC17 as essential for neuronal health and regulated by its own substrate.

   Evidence In vitro reconstitution of HTT-dependent potentiation of SNAP25 palmitoylation; Hip14 KO mouse with palmitoylation assays, behavioral testing, and neuropathology

   PMID:21636527 PMID:21775500

   Open questions at the time

   • Whether HTT acts as allosteric activator or co-substrate not distinguished
   • Adult-specific roles not separated from developmental defects
5. 2013 High

   Electrophysiological and behavioral analysis of Hip14-KO mice revealed marked synaptic dysfunction and impaired hippocampal memory, establishing that a single PAT has major consequences for cognition.

   Evidence Electrophysiological recordings and hippocampal-dependent behavioral tests in Hip14 KO mice

   PMID:24277827

   Open questions at the time

   • Which specific substrate deficits underlie synaptic phenotypes unknown
   • Circuit-level mechanism not resolved
6. 2015 High

   Discovery of the zDABM consensus motif ([VIAP][VIT]XXQP) recognized by the ankyrin repeat domain resolved how ZDHHC17 selects substrates from the proteome, revealing a modular recognition logic shared with ZDHHC13.

   Evidence Peptide array binding assays, co-IP of AR domain with substrates, mutational analysis of binding motif

   PMID:26198635

   Open questions at the time

   • Structural basis of AR–zDABM recognition not solved
   • Whether all palmitoylation substrates require zDABM unknown
7. 2015 Medium

   ZDHHC17 was found to promote axon outgrowth by facilitating TrkA–tubulin complex formation and ERK1/2 signaling independently of its PAT catalytic activity, revealing a non-enzymatic scaffolding function.

   Evidence Zebrafish zdhhc17 LOF, siRNA in NSCs/PC12 cells, co-IP of TrkA–tubulin, PAT-inactive mutant overexpression

   PMID:26232532

   Open questions at the time

   • Non-enzymatic function not independently confirmed
   • Whether ankyrin repeat domain mediates this scaffolding not tested
   • In vivo mammalian validation lacking
8. 2016 High

   Adult-specific conditional deletion showed that HIP14 is required for ongoing neuronal maintenance in the mature brain, causing rapid paralysis, striatal synaptic deficits, and gliosis, separating adult from developmental roles.

   Evidence Inducible conditional KO mice with electrophysiology, histology, and behavioral analysis

   PMID:27927242

   Open questions at the time

   • Which substrates are most critical for adult neuronal survival not defined
   • Glial-autonomous vs. neuronal-autonomous effects not separated
9. 2020 High

   ZDHHC17 was shown to palmitoylate both DLK (enabling somal degeneration) and NMNAT2 (maintaining distal axon integrity) in retinal ganglion cells, demonstrating that a single PAT coordinates two opposing arms of neuronal survival and degeneration.

   Evidence Optic nerve crush model, genetic LOF of ZDHHC17, palmitoylation assays, zDABM motif identification in DLK and NMNAT2

   PMID:33207199

   Open questions at the time

   • Whether ZDHHC17 preference shifts between DLK and NMNAT2 under injury conditions unknown
   • Downstream acylation-site identification on DLK incomplete
10. 2022 Medium

    Demonstration that SPRED3 is efficiently S-acylated by zDHHC17 through a zDABM-independent mechanism involving the SPR domain revealed a second substrate-binding surface outside the ankyrin repeat domain.

    Evidence Mutational analysis of binding motifs, co-IP, resin-assisted capture acylation assays with deletion constructs

    PMID:36442513

    Open questions at the time

    • Identity of the alternative binding surface on ZDHHC17 not mapped
    • Prevalence of zDABM-independent substrates genome-wide unknown
11. 2024 High

    Identification of Smad7 palmitoylation at four cysteines by ZDHHC17, with Cys415/417 palmitoylation driving nuclear-to-cytoplasmic translocation and stabilization, extended ZDHHC17's role into TGF-β signaling regulation.

    Evidence Resin-assisted capture, metabolic labeling, Cys mutagenesis, subcellular fractionation, TGF-β/Smad reporter assays

    PMID:38876303

    Open questions at the time

    • Physiological context (tissue, cell type) for Smad7 palmitoylation in vivo not established
    • Whether ZDHHC17 palmitoylates other Smad family members unknown

• Key unresolved questions include the structural basis for ankyrin repeat–zDABM recognition, how ZDHHC17 activity is regulated beyond HTT interaction, the full scope of zDABM-independent substrates, and whether its non-enzymatic scaffolding functions are physiologically significant in mammals.
• No crystal or cryo-EM structure of ZDHHC17 AR domain bound to zDABM
• Regulatory post-translational modifications of ZDHHC17 itself not systematically characterized
• Non-enzymatic functions not validated in mammalian genetic models